Up-regulation of heparan sulfate 6-O-sulfation in idiopathic pulmonary fibrosis.

Heparan sulfate proteoglycans (HSPGs) are integral components of the lung. Changes in HSPGs have been documented in idiopathic pulmonary fibrosis (IPF). Many of the biological functions of HSPGs are mediated by heparan sulfate (HS) side chains, and little is understood about these side chains in the pathogenesis of IPF. The aims of this study were to compare HS structure between normal and IPF lungs and to examine how changes in HS regulate the fibrotic process. HS disaccharide analysis revealed that HS 6-O-sulfation was significantly increased in IPF lungs compared with normal lungs, concomitant with overexpression of HS 6-O-sulfotransferases 1 and 2 (HS6ST1/2) mRNA. Immunohistochemistry revealed that HS6ST2 was specifically expressed in bronchial epithelial cells, including those lining the honeycomb cysts in IPF lungs, whereas HS6ST1 had a broad expression pattern. Lung fibroblasts in the fibroblastic foci of IPF lungs expressed HS6ST1, and overexpression of HS6ST1 mRNA was observed in primary lung fibroblasts isolated from IPF lungs compared with those from normal lungs. In vitro, small interference RNA-mediated silencing of HS6ST1 in primary normal lung fibroblasts resulted in reduced Smad2 expression and activation and in reduced expression of collagen I and α-smooth muscle actin after TGF-β1 stimulation. Similar results were obtained in primary IPF lung fibroblasts. Furthermore, silencing of HS6ST1 in normal and IPF lung fibroblasts resulted in significant down-regulation of TβRIII (betaglycan). In summary, HS 6-O-sulfation is up-regulated in IPF with overexpression of HS6ST1 and HS6ST2, and overexpression of HS6ST1 in lung fibroblasts may regulate their fibrotic responses to TGF-β1.

[1]  J. Lasky,et al.  Overexpression of Sulf2 in idiopathic pulmonary fibrosis. , 2013, Glycobiology.

[2]  M. Mytilinaiou,et al.  Syndecan‐2 is a key regulator of transforming growth factor beta 2/smad2‐mediated adhesion in fibrosarcoma cells , 2013, IUBMB life.

[3]  S. Stringer,et al.  Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes , 2012, Virchows Archiv.

[4]  Y. Yamaguchi,et al.  Syndecan-2 Is a Novel Target of Insulin-Like Growth Factor Binding Protein-3 and Is Over-Expressed in Fibrosis , 2012, PloS one.

[5]  K. Salmenkivi,et al.  Regulation of TGF-β storage and activation in the human idiopathic pulmonary fibrosis lung , 2012, Cell and Tissue Research.

[6]  P. Albanese,et al.  Age-related Changes in Rat Myocardium Involve Altered Capacities of Glycosaminoglycans to Potentiate Growth Factor Functions and Heparan Sulfate-altered Sulfation* , 2012, The Journal of Biological Chemistry.

[7]  Qin Li,et al.  Silencing of hHS6ST2 inhibits progression of pancreatic cancer through inhibition of Notch signalling. , 2011, The Biochemical journal.

[8]  Ping Liu,et al.  Smad2 and Smad3 as mediators of the response of adventitial fibroblasts induced by transforming growth factor β1. , 2011, Molecular medicine reports.

[9]  M. Königshoff.  Lung Cancer in Pulmonary Fibrosis: Tales of Epithelial Cell Plasticity , 2011, Respiration.

[10]  J. Esko,et al.  Lacrimal Gland Development and Fgf10-Fgfr2b Signaling Are Controlled by 2-O- and 6-O-sulfated Heparan Sulfate* , 2011, The Journal of Biological Chemistry.

[11]  R. Homer,et al.  Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. , 2010, The Journal of clinical investigation.

[12]  T. V. van Kuppevelt,et al.  Heparan Sulfates in the Lung: Structure, Diversity, and Role in Pulmonary Emphysema , 2010, Anatomical record.

[13]  R. Bois,et al.  Strategies for treating idiopathic pulmonary fibrosis , 2010, Nature Reviews Drug Discovery.

[14]  Guoying Yu,et al.  Oxidative Stress Alters Syndecan-1 Distribution in Lungs with Pulmonary Fibrosis* , 2009, Journal of Biological Chemistry.

[15]  K. Meyer,et al.  Review: Therapies for interstitial lung disease: past, present and future , 2008, Therapeutic advances in respiratory disease.

[16]  O. Larsson,et al.  Fibrotic Myofibroblasts Manifest Genome-Wide Derangements of Translational Control , 2008, PloS one.

[17]  Dawn R. Chin,et al.  Transforming Growth Factor-β1 Induces Heparan Sulfate 6-O-Endosulfatase 1 Expression in Vitro and in Vivo* , 2008, Journal of Biological Chemistry.

[18]  K. H. Albrecht,et al.  Systemic inactivation of Hs6st1 in mice is associated with late postnatal mortality without major defects in organogenesis , 2008, Genesis.

[19]  N. Nagai,et al.  Mice Deficient in Heparan Sulfate 6-O-Sulfotransferase-1 Exhibit Defective Heparan Sulfate Biosynthesis, Abnormal Placentation, and Late Embryonic Lethality* , 2007, Journal of Biological Chemistry.

[20]  Thomas Dierks,et al.  The heparanome--the enigma of encoding and decoding heparan sulfate sulfation. , 2007, Journal of biotechnology.

[21]  Jeffrey D. Esko,et al.  Heparan sulphate proteoglycans fine-tune mammalian physiology , 2007, Nature.

[22]  G. Oster,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[23]  D. Price,et al.  Heparan Sulphation Patterns Generated by Specific Heparan Sulfotransferase Enzymes Direct Distinct Aspects of Retinal Axon Guidance at the Optic Chiasm , 2006, The Journal of Neuroscience.

[24]  Melissa A. Rusch,et al.  A unique role for 6-O sulfation modification in zebrafish vascular development. , 2005, Developmental biology.

[25]  D. Livant,et al.  Integrin alpha4beta1 regulates migration across basement membranes by lung fibroblasts: a role for phosphatase and tensin homologue deleted on chromosome 10. , 2003, American journal of respiratory and critical care medicine.

[26]  Y. Matsuda,et al.  Biosynthesis of heparan sulphate with diverse structures and functions: two alternatively spliced forms of human heparan sulphate 6-O-sulphotransferase-2 having different expression patterns and properties. , 2003, The Biochemical journal.

[27]  S. Phan.  The myofibroblast in pulmonary fibrosis. , 2002, Chest.

[28]  V. Poletti,et al.  Abnormal Re-epithelialization and Lung Remodeling in Idiopathic Pulmonary Fibrosis: The Role of ΔN-p63 , 2002, Laboratory Investigation.

[29]  W. Thurlbeck,et al.  Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. , 2001, American journal of respiratory and critical care medicine.

[30]  H. Nakato,et al.  Drosophila Heparan Sulfate 6-O-Sulfotransferase (dHS6ST) Gene , 2001, The Journal of Biological Chemistry.

[31]  M. Selman,et al.  Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. , 2001, American journal of respiratory cell and molecular biology.

[32]  K. Yoshida,et al.  The Occurrence of Three Isoforms of Heparan Sulfate 6-O-Sulfotransferase Having Different Specificities for Hexuronic Acid Adjacent to the TargetedN-Sulfoglucosamine* , 2000, The Journal of Biological Chemistry.

[33]  M. Lyon,et al.  Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. , 1998, Matrix biology : journal of the International Society for Matrix Biology.

[34]  M. Salmivirta,et al.  Age-dependent Modulation of Heparan Sulfate Structure and Function* , 1998, The Journal of Biological Chemistry.

[35]  G. Jayson,et al.  Heparan Sulfate Undergoes Specific Structural Changes during the Progression from Human Colon Adenoma to Carcinoma in Vitro * , 1998, The Journal of Biological Chemistry.

[36]  H. Toyoda,et al.  Sensitive high-performance liquid chromatographic method with fluorometric detection for the determination of heparin and heparan sulfate in biological samples: application to human urinary heparan sulfate. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[37]  M. Lyon,et al.  The Interaction of the Transforming Growth Factor-βs with Heparin/Heparan Sulfate Is Isoform-specific* , 1997, The Journal of Biological Chemistry.

[38]  S. Phan,et al.  Lung fibroblast alpha-smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis. , 1996, The American journal of pathology.

[39]  M. Rekhter,et al.  Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. , 1994, The American journal of pathology.

[40]  J. McDonald,et al.  The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. , 1991, The American journal of pathology.

[41]  D. Penney,et al.  Cell-cell matrix interactions in induced lung injury. II. X-irradiation mediated changes in specific basal laminar glycosaminoglycans. , 1985, International journal of radiation oncology, biology, physics.

[42]  K. Kimata,et al.  Mice deficient in heparan sulfate 6-O-sulfotransferase-1. , 2010, Progress in molecular biology and translational science.

[43]  J. Massagué,et al.  The logic of TGFbeta signaling. , 2006, FEBS letters.

[44]  A. Woods,et al.  Syndecan-2 regulates transforming growth factor-beta signaling. , 2004, The Journal of biological chemistry.

[45]  S. Kojima,et al.  Uptake of 67Ga in the lung of mice during bleomycin treatment , 2004, European Journal of Nuclear Medicine.

[46]  D. Rifkin,et al.  Making sense of latent TGFbeta activation. , 2003, Journal of cell science.

[47]  S. Selleck,et al.  Order out of chaos: assembly of ligand binding sites in heparan sulfate. , 2002, Annual review of biochemistry.

[48]  P. Sannes,et al.  Basement membranes and pulmonary development. , 1997, Experimental lung research.

[49]  菅沼秀基.  Enhanced migration of fibroblasts derived from lungs with fibrotic lesions(線維化肺由来の線維芽細胞における遊走能の亢進) , 1996 .

[50]  J. Massagué,et al.  Betaglycan presents ligand to the TGF beta signaling receptor. , 1993, Cell.